Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

GI05-102

Phase I / Randomized Phase II Study of Second Line Therapy With Irinotecan and Cetuximab With or Without RAD001, an Oral mTOR Inhibitor for Patients With Metastatic Colorectal Cancer: Hoosier Oncology Group GI05-102

ClinicalTrials.gov Identifier: NCT00522665.

Abstracts/Posters/Presentations:

  • S. Shadha, M. Yu, J. Picus, J. Bufill, W. Harb, M. Burns, J. Spittler, J. Flynn, Y.Zeng, G. Vance, C. Currie, J. Wu, P. J. Loehrer, E.G. Chiorean. Phase I study of everolimus (RAD001) with Irinotecan (Iri) and Cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC): Hoosier Oncology Group GI05-102, final report. Accepted as Poster Presentation at General Poster Session at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL. J Clin Oncol 29: 2011 (suppl; abstr 3587).
    See abstract.
  • Chiorean EG, Picus J, Breen T, Ansari RH, Harb WA, Burns M, Spittler AJ, Loehrer PJ. Phase I/II study of everolimus (E) with irinotecan (Iri) and cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC): Hoosier Cancer Research Network GI05-102. Accepted as Poster Presentation at General Poster Session at the ASCO Annual Meeting, May 29-June 2, 2015, Chicago IL. J Clin Oncol 33:5s, 2015 (suppl; abstr 3618).
    See abstract.